GNS Announces Collaboration with BMS
No financial terms were disclosed on the tie-up, under which GNS will take clinical and molecular information from a BMS clinical trial and will use its supercomputer-driven REFS (reverse-engineering and forward-simulation) platform to construct a comprehensive inflammation disease model “directly from the raw data”.
This patient data comprises of genetic information, gene expression levels, specific blood markers and clinical outcomes that can help BMS to identify key molecular mechanisms and biomarkers in immuno-inflammation.
The resulting disease model will support virtual clinical trials that simulate the clinical impact of inhibiting various drug targets and help to predict novel molecular targets for combating immuno-inflammation, effective in specific types of patients.
Dr Iya Khalil, executive vice president and co-founder of GNS Healthcare, commented that “this is the first step in building a significantly advanced in silico research paradigm that may enable development of new therapies based directly on human data, and address the needs of patients with particular genetics and molecular phenotypes, ultimately enabling the optimisation of individualised patient outcomes”.
Licensed to GNS from its parent company Via Science, the REFS platform comprises of integrated machine learning algorithms and software that extract “causal” relationships from complex, multi-dimensional data and enable the simulation of billions of “what if?” hypotheses to explore novel unseen conditions and predictions forward in time.
GNS uses the technology to optimise patient treatments in partnership with health insurance companies, pharmacy benefit managers and healthcare providers as well as pharmaceutical and biotechnology companies.